866-997-4948(US-Canada Toll Free)

Peritoneal Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 124 Pages


Global Markets Directs, Peritoneal Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Peritoneal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Peritoneal Cancer.
  • A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Peritoneal Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Peritoneal Cancer 9
Peritoneal Cancer Therapeutics under Development by Companies 11
Peritoneal Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Peritoneal Cancer Therapeutics Products under Development by Companies 18
Peritoneal Cancer Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Peritoneal Cancer Therapeutics Development 20
AstraZeneca PLC 20
GlaxoSmithKline plc 21
Oxford BioMedica plc 22
Millennium Pharmaceuticals, Inc. 23
Novartis AG 24
Bayer AG 25
Incyte Corporation 26
EntreMed, Inc. 27
Oncolytics Biotech Inc. 28
Synta Pharmaceuticals Corp. 29
Oasmia Pharmaceutical AB 30
Spectrum Pharmaceuticals, Inc. 31
Acceleron Pharma, Inc. 32
TRION Pharma GmbH 33
TetraLogic Pharmaceuticals 34
CritiTech, Inc. 35
ImmunoVaccine Technologies Inc. 36
VentiRx Pharmaceuticals, Inc. 37
Genelux Corporation 38
Peritoneal Cancer Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
sorafenib tosylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
selumetinib sulfate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ENMD-2076 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
dalantercept - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
elesclomol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
paclitaxel - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TroVax - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MEK-162 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pelareorep - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
catumaxomab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
VTX-2337 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
paclitaxel - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
OC-DC Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pazopanib hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
INCB-24360 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
birinapant - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MV-NIS Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TALL-104 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate + [QS-21] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
metformin - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Theranean - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Peritoneal Cancer Therapeutics Drug Profile Updates 91
Peritoneal Cancer Therapeutics Discontinued Products 117
Peritoneal Cancer Therapeutics - Dormant Products 118
Peritoneal Cancer Product Development Milestones 120
Featured News & Press Releases 120
Nov 01, 2012: Genelux Announces Early Results Of Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers 120
Sep 20, 2012: Roches Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 121
May 31, 2012: Genelux Announces Treatment Of First Patient In Phase I/II Clinical Trial Of GL-ONC1 In Advanced Peritoneal Cavity Cancers 122

Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 124
Disclaimer 124

List of Table


Number of Products Under Development for Peritoneal Cancer, H2 2013 9
Products under Development for Peritoneal Cancer Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
AstraZeneca PLC, H2 2013 20
GlaxoSmithKline plc, H2 2013 21
Oxford BioMedica plc, H2 2013 22
Novartis AG, H2 2013 24
Bayer AG, H2 2013 25
Incyte Corporation, H2 2013 26
EntreMed, Inc., H2 2013 27
Oncolytics Biotech Inc., H2 2013 28
Synta Pharmaceuticals Corp., H2 2013 29
Oasmia Pharmaceutical AB, H2 2013 30
Acceleron Pharma, Inc., H2 2013 32
TRION Pharma GmbH, H2 2013 33
TetraLogic Pharmaceuticals, H2 2013 34
CritiTech, Inc., H2 2013 35
VentiRx Pharmaceuticals, Inc., H2 2013 37
Assessment by Monotherapy Products, H2 2013 39
Assessment by Combination Products, H2 2013 40
Assessment by Stage and Route of Administration, H2 2013 42
Assessment by Stage and Molecule Type, H2 2013 44
Peritoneal Cancer Therapeutics Drug Profile Updates 91
Peritoneal Cancer Therapeutics Discontinued Products 117
Peritoneal Cancer Therapeutics Dormant Products 118
Peritoneal Cancer Therapeutics Dormant Products (Contd..1) 119

List of Chart


Number of Products under Development for Peritoneal Cancer, H2 2013 9
Products under Development for Peritoneal Cancer Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 39
Assessment by Combination Products, H2 2013 40
Assessment by Route of Administration, H2 2013 41
Assessment by Stage and Route of Administration, H2 2013 42
Assessment by Molecule Type, H2 2013 43
Assessment by Stage and Molecule Type, H2 2013 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *